Gareth Davies
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gareth Davies has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Arthur Lewis
Department of General Agriculture, Faculty of Applied Science and Technology, Sunyani Technical University, Sunyani, Ghana
39 shared publications - Benjamin Ferman
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania
39 shared publications - Daniel J. Powell
University of Pennsylvania 5 Philadelphia, PA
39 shared publications - E. Jessica. Tang
Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
39 shared publications - Eric Brown
Department of Cancer Biology and the Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
39 shared publications - Fiona Simpkins
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA
39 shared publications
Latest Publications
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Western blot primary antibodies and dilution.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Western blot primary antibodies and dilution.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
B7-H4 cell surface expression in cell lines and B7-H4-ADC cytotoxicity.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
B7-H4 cell surface expression in cell lines and B7-H4-ADC cytotoxicity.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Representative B7-H4 immunohistochemistry.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Representative B7-H4 immunohistochemistry.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Flow plots for yH2AX expression after B7-H4-ADC treatment.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Flow plots for yH2AX expression after B7-H4-ADC treatment.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Flow plots for cell cycle arrest after B7-H4-ADC treatment.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Flow plots for cell cycle arrest after B7-H4-ADC treatment.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Immunohistochemical analysis of PDX tumors for Ki67 after ADC treatment.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Immunohistochemical analysis of PDX tumors for Ki67 after ADC treatment.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Summary of cell lines growth conditions.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Summary of cell lines growth conditions.
- Open Access
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Individual mouse data and statistical analysis of WO-19 PDX in vivo study.
- 15 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Individual mouse data and statistical analysis of WO-19 PDX in vivo study.